These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

100 related articles for article (PubMed ID: 20404464)

  • 1. Infection with hepatitis C virus genotype 3--experience of a tertiary health care centre in south India.
    David J; Rajasekar A; Daniel HD; Ngui SL; Ramakrishna B; Zachariah UG; Eapen CE; Abraham P
    Indian J Med Microbiol; 2010; 28(2):155-7. PubMed ID: 20404464
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapid virological response as a predictor of sustained response in HCV-infected patients with persistently normal alanine aminotransferase levels: A multicenter study.
    Puoti C; Barbarini G; Picardi A; Romano M; Pellicelli A; Barlattani A; Mecenate F; Guarisco R; Costanza OM; Spilabotti L; Bellis L; Bonaventura ME; Dell' Unto O; Elmo MG; Nicolini AM; Nosotti L; Soccorsi F;
    J Viral Hepat; 2011 Jun; 18(6):393-9. PubMed ID: 20546499
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Predictive factors of early and sustained responses to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b: amino acid substitutions in the core region and low-density lipoprotein cholesterol levels.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Hepatol; 2007 Mar; 46(3):403-10. PubMed ID: 17126448
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Predictive value of complete and partial early virological response on sustained virological response rates of genotype-4 chronic hepatitis C patients treated with PEG-interferon plus ribavirin.
    Elefsiniotis IS; Vezali E; Mihas C; Saroglou G
    Intervirology; 2009; 52(5):247-51. PubMed ID: 19602898
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Role of rapid virological response in prediction of sustained virological response to Peg-IFN plus ribavirin in HCV / HIV co-infected individuals.
    Shea DO; Tuite H; Farrell G; Codd M; Mulcahy F; Norris S; Bergin C
    J Viral Hepat; 2008 Jul; 15(7):482-9. PubMed ID: 18221297
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Predictive value of rapid virological response and early virological response on sustained virological response in HCV patients treated with pegylated interferon alpha-2a and ribavirin.
    Yu JW; Wang GQ; Sun LJ; Li XG; Li SC
    J Gastroenterol Hepatol; 2007 Jun; 22(6):832-6. PubMed ID: 17565637
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Efficacy of low-dose intermittent interferon-alpha monotherapy in patients infected with hepatitis C virus genotype 1b who were predicted or failed to respond to pegylated interferon plus ribavirin combination therapy.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2008 Aug; 80(8):1363-9. PubMed ID: 18551610
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Undetectable hepatitis C virus RNA at week 4 as predictor of sustained virological response in HIV patients with chronic hepatitis C.
    Martin-Carbonero L; Nuñez M; Mariño A; Alcocer F; Bonet L; García-Samaniego J; López-Serrano P; Cordero M; Portu J; Soriano V
    AIDS; 2008 Jan; 22(1):15-21. PubMed ID: 18090387
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Treatment of acute HCV infection in HIV-positive patients: experience from a multicentre European cohort.
    Vogel M; Dominguez S; Bhagani S; Azwa A; Page E; Guiguet M; Valantin MA; Katlama C; Rockstroh JK; Nelson M
    Antivir Ther; 2010; 15(2):267-79. PubMed ID: 20386082
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Early discontinuation of ribavirin in HCV-2 and HCV-3 patients responding to Peg-interferon alpha-2a and ribavirin.
    Andriulli A; Cursaro C; Cozzolongo R; Iacobellis A; Valvano MR; Mangia A; Minerva N; Bacca D; Stanzione M; Scuteri A; Montalto G; Andreone P
    J Viral Hepat; 2009 Jan; 16(1):28-35. PubMed ID: 18761603
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The use of trough ribavirin concentration to predict sustained virological response and haematological toxicity in HIV/HCV-co-infected patients treated with ribavirin and pegylated interferon.
    Aguilar Marucco D; Gonzalez de Requena D; Bonora S; Tettoni C; Bonasso M; De Blasi T; D'Avolio A; Sciandra M; Siccardi M; Baietto L; Trentini L; Sinicco A; Cariti G; Di Perri G
    J Antimicrob Chemother; 2008 Apr; 61(4):919-24. PubMed ID: 18238889
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Results of a study of prolonging treatment with pegylated interferon-alpha2a plus ribavirin in HIV/HCV-coinfected patients with no early virological response.
    Fuster D; Planas R; Gonzalez J; Force L; Cervantes M; Vilaró J; Roget M; García I; Pedrol E; Tor J; Ballesteros AL; Salas A; Sirera G; Videla S; Clotet B; Tural C
    Antivir Ther; 2006; 11(4):473-82. PubMed ID: 16856621
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Differential viral kinetics in treated genotype 4 chronic hepatitis C patients according to ethnicity.
    Elefsiniotis IS; Pavlidis C; Dimitroulopoulos D; Vezali E; Mihas C; Mariolis-Sapsakos T; Koutsounas S; Paraskevas E; Saroglou G
    J Viral Hepat; 2009 Oct; 16(10):738-42. PubMed ID: 19413697
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Critical role of ribavirin for the achievement of early virological response to HCV therapy in HCV/HIV-coinfected patients.
    Ramos B; Núñez M; Rendón A; Berdún MA; Losada E; Santos I; Echevarría S; Ocampo A; Miralles C; Arazo P; Barreiro P; Romero M; Labarga P; Guardiola JM; Garcia-Samaniego J; Soriano V
    J Viral Hepat; 2007 Jun; 14(6):387-91. PubMed ID: 17501758
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Predictors of viral kinetics to peginterferon plus ribavirin combination therapy in Japanese patients infected with hepatitis C virus genotype 1b.
    Akuta N; Suzuki F; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Arase Y; Ikeda K; Kumada H
    J Med Virol; 2007 Nov; 79(11):1686-95. PubMed ID: 17854035
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Recurrent hepatitis C after liver transplantation: on-treatment prediction of response to peginterferon/ribavirin therapy.
    Hanouneh IA; Miller C; Aucejo F; Lopez R; Quinn MK; Zein NN
    Liver Transpl; 2008 Jan; 14(1):53-8. PubMed ID: 18161839
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Extending combination therapy with peginterferon plus ribavirin for genotype 2 chronic hepatitis C virological responders: a pilot study of 7 cases.
    Akuta N; Suzuki F; Arase Y; Hirakawa M; Kawamura Y; Yatsuji H; Sezaki H; Suzuki Y; Hosaka T; Kobayashi M; Kobayashi M; Saitoh S; Ikeda K; Kumada H
    Intervirology; 2010; 53(3):188-92. PubMed ID: 20197686
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Combined treatment with pegylated interferon (alpha-2b) and ribavirin in the acute phase of hepatitis C virus recurrence after liver transplantation.
    Castells L; Vargas V; Allende H; Bilbao I; Luis Lázaro J; Margarit C; Esteban R; Guardia J
    J Hepatol; 2005 Jul; 43(1):53-9. PubMed ID: 15876467
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Efficacy of an escalating dose regimen of pegylated interferon alpha-2a plus ribavirin in the early phase of HCV reinfection after liver transplantation.
    Zimmermann T; Böcher WO; Biesterfeld S; Zimmermann A; Kanzler S; Greif-Higer G; Barreiros AP; Sprinzl MF; Wörns MA; Lohse AW; Mönch C; Otto G; Galle PR; Schuchmann M
    Transpl Int; 2007 Jul; 20(7):583-90. PubMed ID: 17433090
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Characteristics and outcomes of HCV genotype-1-infected patients treated with peginterferon and ribavirin combination therapy with discordant HCV responses 4 and 12 weeks after starting therapy.
    Toyoda H; Kumada T; Shimada N; Takaguchi K; Ide T; Sata M; Ginba H; Matsuyama K; Izumi N
    Intervirology; 2014; 57(5):289-96. PubMed ID: 24992890
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.